These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27707550)

  • 1. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
    Sepah YJ; Sadiq MA; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus D; Halperin L; Hassan M; Campochiaro PA; Nguyen QD; Do DV;
    Ophthalmology; 2016 Dec; 123(12):2581-2587. PubMed ID: 27707550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).
    Do DV; Sepah YJ; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus DM; Halperin L; Sadiq MA; Rajagopalan N; Campochiaro PA; Nguyen QD;
    Eye (Lond); 2015 Dec; 29(12):1538-44. PubMed ID: 26228291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes.
    Zucchiatti I; Bandello F
    Dev Ophthalmol; 2017; 60():63-70. PubMed ID: 28427066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R; Lu N; Campochiaro PA
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study.
    Sadiq MA; Soliman MK; Sarwar S; Agarwal A; Hanout M; Demirel S; Rentiya ZS; Khan W; Do DV; Nguyen QD; Sepah YJ;
    Ophthalmology; 2016 Feb; 123(2):324-329. PubMed ID: 26520169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.